References
[1] Z.-Q. Y. C. L. S.-J. C. Q. S. T.-R. Z. N. S. P. Z.-P. Y. J.-M. Y. Ji-Wei Wang. (2016). “Cancer survivors’ perspectives and ex-perience on western medicine and traditional Chinese medicine treatment and rehabilitation: a qualitative study,” Patient Preference and Adherence, pp. 2-6, 2016.
[2] M. H. M. Z. S. Z. L. C. H. Z. H. Y. L. Qiang Sun. (2021). “Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery,” Systematic review, 2021.
[3] C. T. S. Y. e. a. Lee YW. (2015). “Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer,” 120: 1338-1344, 2015.
[4] A. F. B. G. I. A. P. M. T. A. T. L. V. K. e. a. Almeida. (2018). “Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation. Compr. Rev. Food Sci. Food Saf.,” pp. 17, 714-731, 2018.
[5] B. N. P. C. L. G. E. M. Smithson J. (2016). “The experience of using complementary therapies after a diagnosis of cancer: a qualitative synthesis. Health (London).,” 16: 19-39, 2016.
[6] A. P. Madan RA. (2013). “Recent advances revolutionize treatment of metastatic prostate cancer. Future Oncol,” 9: 1133-1144., 2013.
[7] I. M.-R. A. G. R. R. J. a. R. M. Andújar. (2018). “Shikonin Prevents Early Phase Inflammation Associated with Azoxymethane/Dextran Sulfate Sodium-Induced Colon Cancer and Induces Apoptosis in Human Colon Cancer Cells. Planta Med.,” pp. 674-683, 2018.
[8] L. D. O. Z. F. L. F. C. J.-F. P. C. e. a. Bu. (2020). “Traditional Chinese Medicine Formulas, Extracts, and Compounds Promote Angiogenesis. Biomed. Pharmacother.,” pp. 132, 110855., 2020.
[9] E. E. L. M. e. a. McCorkle R. (2013). “Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin.,” 61: 50-62., 2013.
[10] S. I. E. M. e. a. Ferlay J. (2017). “Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11,” International Agency for Research on Cancer, 2017.
[11] C. S. P. B. A. a. S. M. Buhrmann. (2020). “Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment,” 2020.
[12] W. L. L. J. L. S. W. Q. Wang Y. (2015). “Comparison and analysis of the incidence and mortality rate of cancer in developed and developing countries. Chin J Clin Oncol.,” 39: 679-682., 2015.
[13] F. A. M. W. M. F. M. P. G. D. Psutka SP. (2014). “Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol.,” 63: 486-492, 2014.
[14] Y.-T. C. F. Z. C. F. B. T. H.-Y. N. H. e. a. Chan. (2020). “Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. Front. Pharmacol.,” 2020.
[15] H.-R. N. Yen. (2021). “Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,” China Medical University Hospital, 2021.
[16] L. Z. H. F. J. L. C. L. Z. C. R. e. a. Chu. (2015). “The Traditional Chinese Medicinal Formula BDL301 Suppresses Tumor Growth by Inhibiting STAT3 Pathway and Inducing Apoptosis in Colorectal Cancer Cells. DNA Cel Biol.,” pp. 34, 178-188, 2015.
[17] S. H. B. A. H.-M. D. Q. X. L. S. K.-P. e. a. Deng. (2014). “Teng-Long-Bu-Zhong-Tang, a Chinese Herbal Formula, Enhances Anticancer Effects of 5 - Fluorouracil in CT26 colon Carcinoma. BMC Complement. Altern. Med.,” pp. 13, 128, 2014.
[18] J. L. L. L. J. Y. C. Z. H. a. L. L. Dong. (2018). “Philosophical Thinking of Chinese Traditional Medicine. Tradit. Med.,” pp. 1-10, 2018.
[19] Y. M. Z. Z. L. W. W. G. M. J. X. e. a. Fan. (2020). “Anti-tumor Activities and Mechanisms of Traditional Chinese Medicines Formulas: A Review. Biomed. Pharmacother,” 2020.
[20] W. A. H. P. C. a. Y. D. Feng. (2019). “Gut Microbiota, a New Frontier to Understand Traditional Chinese Medicines. Pharmacol. Res.,” pp. 142, 176-191, 2019.
[21] T. W. W. H. L. K. Liu CH1. (2013). “Cancer patients’ experience of combined treatment with conventional and traditional Chinese medicine: a biopsychosocial phenomenon. Cancer Nurs.,” 34(6): 495-502, 2013.